Manager People Analytics & Insights
About the job
- Experience: 8–12 years of experience in data analytics, people analytics, or a closely related discipline, with demonstrated experience owning analytical domains and driving insight-led decisions at a senior level in complex organizations.
- Education: Degree-level qualification (or equivalent) in Data Analytics, Statistics, Economics, Organizational Psychology, Human Resources, or a related field. Postgraduate qualification or equivalent depth of practice is an advantage.
- Technical Depth: Expert proficiency in BI tools (e.g. Power BI, Tableau) and Excel; advanced SQL; strong working proficiency in Python or R, including applying statistical or predictive methods to workforce data. Actively uses AI tools to enhance the quality and efficiency of analytical work.
- Methodological Range: Able to design as well as apply analytical methods - including regression modelling, clustering, attrition prediction, or scenario modelling - and judge which approach is right for the problem, not just the tool at hand.
- Framework & Standards Design: Demonstrated ability to design metrics frameworks, define analytical standards, or build scalable reporting infrastructure that others can work to.
- HR Systems & Data Governance: Deep familiarity with HR data platforms (e.g. Workday, SAP SuccessFactors), data structures, and governance considerations, including multi-country and GDPR complexity.
- Influence & Communication: Proven ability to shape how senior stakeholders think, not just reporting findings, but persuading, reframing, and leading discussions with credibility and composure under challenge.
- Autonomy: Consistently works independently on ambiguous, high-stakes problems. Comfortable operating where the question is unclear, the data is imperfect, and the answer matters.
- Domain Ownership: Sets the analytical agenda of Talent Acquisition and Talent Development, defining relevant metrics, and ensuring outputs are consistently high quality, strategically relevant, and aligned to organizational priorities.
- Complex & Ambiguous Analysis: Lead end-to-end analysis of complex problems, independently framing the question, selecting or developing the appropriate methodology, and delivering findings that meaningfully shift understanding or decision-making.
- Stakeholder Influence: Engage senior HR and business stakeholders not just to explain findings, but to shape how they think about problems, influencing approach and direction.
- Insight Narrative & Recommendations: Develop well-reasoned, evidence-based recommendations.
- Data Quality & Governance Standards: Take accountability for the integrity and governance of people data within the domain, driving resolution across systems and process owners and contributing to enterprise-wide data standards.
- Informal Leadership: Provide ongoing coaching and quality review for junior analysts, reviewing outputs, developing analytical capability, and raising team standards through day-to-day collaboration.
- Innovation & Continuous Improvement: Proactively identify where existing approaches, models, or processes are insufficient and develop new ones, building new analytical capabilities where gaps exist.
- Benchmarking & External Perspectives: Lead benchmarking and external research initiatives, interpreting comparative data in context and synthesizing external trends into actionable implications for the organization.
- Advanced Analytics in a Workforce Context: Hands-on experience applying predictive or machine learning techniques to people data - attrition modelling, skills clustering, internal mobility analysis, or similar.
- Cross-Domain People Analytics: Experience spanning more than one analytics domain - e.g. engagement, succession planning, workforce planning, and DEI - with the ability to connect insights across them.
- Global & Multi-Jurisdictional Data: Experience managing and interpreting datasets across multiple geographies, including navigating data privacy constraints.
- Consulting or Embedded Advisory Experience: Background in a consulting environment or internal advisory role, with experience leading workstreams, managing stakeholder expectations, and delivering under defined accountability.
About the company
CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.
Company Size
10,001+
Company Stage
IPO
Headquarters
Parkville, Australia
Founded
1916
Get referred to CSL
See people who can refer or advise you
Simplify's Take
What believers are saying
- CSL reported US$176 million FY26 cost savings, ahead of its transformation target.
- US military flu-vaccine exceptions restored some demand after April 2026 mandate cuts.
- VarmX’s 2029 coagulation program gives CSL a new high-value pipeline beyond plasma.
What critics are saying
- FY26 statutory loss hit US$2.6 billion after US$7.1 billion impairments and restructuring.
- CSL plans US$400 million FY27 savings, implying more closures, layoffs, and execution friction.
- The U.S. plasma turnaround depends on Horizon 2; failure risks long-term margin collapse.
What makes CSL unique
- CSL’s FY26 revenue reached US$15.8 billion across plasma, vaccines, and Vifor.
- Seqirus’ AUJEMFLU won UK and European approvals, backed by Lancet Phase 3 data.
- HEMGENIX remains Europe’s first approved hemophilia B gene therapy, strengthening CSL Behring.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
Growth & Insights and Company News
6 month growth
0%1 year growth
0%2 year growth
1%Haemonetics shares jumped 12% after the company announced CSL now expects to move all of its current US plasma collection centres to Haemonetics' NexSys devices by the end of 2027. The deal, first disclosed in August, was initially limited to only a portion of CSL's US centres with no timeline. The expanded agreement is significant because losing CSL previously flattened Haemonetics' growth. In fiscal 2026, the company's organic revenue growth was just 1.1%, compared to 9.5% excluding lost CSL sales. Following the surge, Haemonetics trades at approximately 21 times forward earnings, above its five-year average of 19.1 times. The deal is non-exclusive with no minimum purchase requirements, meaning CSL can still modify scope and timing. Management plans to provide further details during its November earnings call.
CSL has raised US$1.5 billion through corporate bonds issued in the United States to refinance existing debt. The Australian biotechnology company turned to offshore debt markets for the transaction. The bond issuance allows CSL to manage its capital structure by replacing current borrowings with new financing secured from US investors.
Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s...
CSL Seqirus has published Phase 3 study results in The Lancet Infectious Diseases for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine for older adults. The vaccine, marketed as AUJEMFLU, combines three proven approaches: MF59 adjuvant, cell-based manufacturing, and higher-dose formulation. The randomised study enrolled 7,699 adults aged 50 and older across eight countries. Results demonstrated superiority versus an adjuvanted egg-based comparator across all four influenza strains and age groups. The vaccine showed non-inferiority versus a recombinant vaccine for three of four strains in the 50-plus age group and all four strains in those aged 65-plus. The trivalent formulation received approval from the UK's MHRA and the European Commission earlier this year for adults aged 50 and above. Regulatory submissions have been made in multiple markets.
Australian biopharmaceutical company CSL reported a 2% decline in annual profit on Tuesday, as its core plasma division experienced falling revenue. The company posted an underlying net profit after tax of $3.14 billion on a constant currency basis for the year ended 30 June, down from $3.22 billion the previous year. CSL is among the world's leading flu vaccine manufacturers. The results reflect challenges in the plasma business, which forms a significant part of the company's operations.